Dr. Athena Philis-Tsimikas, an endocrinologist at Scripps Clinic and corporate vice president of the Scripps Whittier Diabetes Institute, lauds the recent FDA decision to greenlight the first over-the-counter continuous glucose monitoring (CGM) system. In a recent article on Healio, Dr. Tsimikas expresses excitement over the implications of this approval, not only for individuals with diabetes but also those without the condition.
The accessibility of an OTC CGM device holds promise for a broader understanding of metabolic health. Dr. Tsimikas highlights the potential for immediate insights into the impacts of factors like diet, exercise, sleep, and stress on glucose levels. While recognizing the hurdles of affordability and access, particularly for underserved communities, she emphasizes the need to address these disparities.
Moreover, Dr. Tsimikas underscores the potential benefits for individuals at risk of diabetes, including those with prediabetes. However, she notes the importance of further research to ascertain the effectiveness of CGM in this population.
For non-diabetic users, Dr. Tsimikas cautions about interpreting glucose readings, particularly regarding hypoglycemic ranges. She emphasizes the need for education and awareness to mitigate potential anxiety associated with abnormal readings.
Dr. Tsimikas sees the FDA's approval of OTC CGM as a step towards empowering individuals to manage their health proactively. With continued research and education, this technology holds immense promise in revolutionizing healthcare outcomes.